AAPL347.73-0.50 (-0.14%) ▼|ABBV285.64+0.45 (+0.16%) ▲|ABT103.70+1.19 (+1.16%) ▲|ACN249.37-9.37 (-3.62%) ▼|ADBE263.82-6.73 (-2.49%) ▼|AMAT377.24+1.66 (+0.44%) ▲|AMD516.79+8.86 (+1.74%) ▲|AMGN439.26-8.02 (-1.79%) ▼|AMT188.97+7.40 (+4.08%) ▲|AMZN248.00-2.38 (-0.95%) ▼|AVGO321.68-1.56 (-0.48%) ▼|AXP313.22-11.95 (-3.68%) ▼|BA188.35+0.80 (+0.43%) ▲|BAC50.56-0.52 (-1.02%) ▼|BKNG155.83-5.27 (-3.27%) ▼|BLK1,118.25-19.04 (-1.67%) ▼|BMY61.48-1.52 (-2.41%) ▼|BNY145.27-0.05 (-0.03%) ▼|BRK-B542.19-4.78 (-0.87%) ▼|C120.62-1.89 (-1.54%) ▼|CAT687.00-17.05 (-2.42%) ▼|CL94.04-3.35 (-3.44%) ▼|CMCSA22.69-0.15 (-0.66%) ▼|COF201.34-2.09 (-1.03%) ▼|COP150.80+5.17 (+3.55%) ▲|COST1,003.32-14.89 (-1.46%) ▼|CRM248.57-1.72 (-0.69%) ▼|CSCO106.50+1.61 (+1.53%) ▲|CVS93.47-1.01 (-1.07%) ▼|CVX233.21+6.53 (+2.88%) ▲|DE646.15+2.53 (+0.39%) ▲|DHR230.50+0.75 (+0.33%) ▲|DIS112.52-0.61 (-0.54%) ▼|DUK124.98-0.42 (-0.33%) ▼|EMR161.59+1.30 (+0.81%) ▲|FDX298.72-5.20 (-1.71%) ▼|GD349.36-1.43 (-0.41%) ▼|GE285.64-7.90 (-2.69%) ▼|GEV815.00-12.42 (-1.50%) ▼|GILD156.04-1.15 (-0.73%) ▼|GM75.92-1.29 (-1.67%) ▼|GOOG317.28-3.48 (-1.08%) ▼|GOOGL320.21-4.01 (-1.24%) ▼|GS875.68-15.62 (-1.75%) ▼|HD319.83-7.90 (-2.41%) ▼|HON221.15+2.84 (+1.30%) ▲|IBM253.56+1.45 (+0.58%) ▲|INTC86.96+1.47 (+1.72%) ▲|INTU343.39-11.51 (-3.24%) ▼|ISRG452.29+8.44 (+1.90%) ▲|JNJ263.81-3.80 (-1.42%) ▼|JPM331.58-4.96 (-1.47%) ▼|KO92.71-2.63 (-2.76%) ▼|LIN508.83-1.53 (-0.30%) ▼|LLY1,273.46-33.23 (-2.54%) ▼|LMT604.18+14.27 (+2.42%) ▲|LOW198.68-5.69 (-2.78%) ▼|LRCX230.10-0.05 (-0.02%) ▼|MA623.60-9.61 (-1.52%) ▼|MCD248.46-4.17 (-1.65%) ▼|MDLZ63.80-1.39 (-2.13%) ▼|MDT95.41-1.18 (-1.22%) ▼|META642.62-6.23 (-0.96%) ▼|MMM173.46-2.10 (-1.20%) ▼|MO74.31-1.76 (-2.31%) ▼|MRK145.27-1.97 (-1.34%) ▼|MS179.49-4.48 (-2.44%) ▼|MSFT524.51+3.43 (+0.66%) ▲|MU877.55+21.06 (+2.46%) ▲|NEE82.10+0.20 (+0.24%) ▲|NFLX65.85-1.20 (-1.79%) ▼|NKE37.30-1.02 (-2.66%) ▼|NOW158.96+1.96 (+1.25%) ▲|NVDA210.96-1.25 (-0.59%) ▼|ORCL126.16+0.62 (+0.49%) ▲|PEP135.77-3.06 (-2.20%) ▼|PFE30.03-0.39 (-1.28%) ▼|PG161.02-3.48 (-2.12%) ▼|PLTR196.75+0.56 (+0.29%) ▲|PM199.47-2.27 (-1.13%) ▼|QCOM175.91+3.08 (+1.78%) ▲|RTX191.01-3.70 (-1.90%) ▼|SBUX100.80-1.11 (-1.09%) ▼|SCHW90.58-0.86 (-0.94%) ▼|SO92.89-0.93 (-0.99%) ▼|SPG211.63-0.41 (-0.19%) ▼|T20.93-1.81 (-7.96%) ▼|TMO673.82-2.72 (-0.40%) ▼|TMUS146.54-12.25 (-7.71%) ▼|TSLA372.22-2.36 (-0.63%) ▼|TXN284.69+5.19 (+1.86%) ▲|UBER66.70-2.37 (-3.43%) ▼|UNH418.09-6.89 (-1.62%) ▼|UNP292.87-5.22 (-1.75%) ▼|UPS101.06-0.46 (-0.45%) ▼|USB59.58-0.44 (-0.73%) ▼|V407.92-6.42 (-1.55%) ▼|VZ44.66-0.54 (-1.19%) ▼|WFC82.39-0.62 (-0.75%) ▼|WMT119.89-1.23 (-1.02%) ▼|XOM183.21+4.98 (+2.79%) ▲|AAPL347.73-0.50 (-0.14%) ▼|ABBV285.64+0.45 (+0.16%) ▲|ABT103.70+1.19 (+1.16%) ▲|ACN249.37-9.37 (-3.62%) ▼|ADBE263.82-6.73 (-2.49%) ▼|AMAT377.24+1.66 (+0.44%) ▲|AMD516.79+8.86 (+1.74%) ▲|AMGN439.26-8.02 (-1.79%) ▼|AMT188.97+7.40 (+4.08%) ▲|AMZN248.00-2.38 (-0.95%) ▼|AVGO321.68-1.56 (-0.48%) ▼|AXP313.22-11.95 (-3.68%) ▼|BA188.35+0.80 (+0.43%) ▲|BAC50.56-0.52 (-1.02%) ▼|BKNG155.83-5.27 (-3.27%) ▼|BLK1,118.25-19.04 (-1.67%) ▼|BMY61.48-1.52 (-2.41%) ▼|BNY145.27-0.05 (-0.03%) ▼|BRK-B542.19-4.78 (-0.87%) ▼|C120.62-1.89 (-1.54%) ▼|CAT687.00-17.05 (-2.42%) ▼|CL94.04-3.35 (-3.44%) ▼|CMCSA22.69-0.15 (-0.66%) ▼|COF201.34-2.09 (-1.03%) ▼|COP150.80+5.17 (+3.55%) ▲|COST1,003.32-14.89 (-1.46%) ▼|CRM248.57-1.72 (-0.69%) ▼|CSCO106.50+1.61 (+1.53%) ▲|CVS93.47-1.01 (-1.07%) ▼|CVX233.21+6.53 (+2.88%) ▲|DE646.15+2.53 (+0.39%) ▲|DHR230.50+0.75 (+0.33%) ▲|DIS112.52-0.61 (-0.54%) ▼|DUK124.98-0.42 (-0.33%) ▼|EMR161.59+1.30 (+0.81%) ▲|FDX298.72-5.20 (-1.71%) ▼|GD349.36-1.43 (-0.41%) ▼|GE285.64-7.90 (-2.69%) ▼|GEV815.00-12.42 (-1.50%) ▼|GILD156.04-1.15 (-0.73%) ▼|GM75.92-1.29 (-1.67%) ▼|GOOG317.28-3.48 (-1.08%) ▼|GOOGL320.21-4.01 (-1.24%) ▼|GS875.68-15.62 (-1.75%) ▼|HD319.83-7.90 (-2.41%) ▼|HON221.15+2.84 (+1.30%) ▲|IBM253.56+1.45 (+0.58%) ▲|INTC86.96+1.47 (+1.72%) ▲|INTU343.39-11.51 (-3.24%) ▼|ISRG452.29+8.44 (+1.90%) ▲|JNJ263.81-3.80 (-1.42%) ▼|JPM331.58-4.96 (-1.47%) ▼|KO92.71-2.63 (-2.76%) ▼|LIN508.83-1.53 (-0.30%) ▼|LLY1,273.46-33.23 (-2.54%) ▼|LMT604.18+14.27 (+2.42%) ▲|LOW198.68-5.69 (-2.78%) ▼|LRCX230.10-0.05 (-0.02%) ▼|MA623.60-9.61 (-1.52%) ▼|MCD248.46-4.17 (-1.65%) ▼|MDLZ63.80-1.39 (-2.13%) ▼|MDT95.41-1.18 (-1.22%) ▼|META642.62-6.23 (-0.96%) ▼|MMM173.46-2.10 (-1.20%) ▼|MO74.31-1.76 (-2.31%) ▼|MRK145.27-1.97 (-1.34%) ▼|MS179.49-4.48 (-2.44%) ▼|MSFT524.51+3.43 (+0.66%) ▲|MU877.55+21.06 (+2.46%) ▲|NEE82.10+0.20 (+0.24%) ▲|NFLX65.85-1.20 (-1.79%) ▼|NKE37.30-1.02 (-2.66%) ▼|NOW158.96+1.96 (+1.25%) ▲|NVDA210.96-1.25 (-0.59%) ▼|ORCL126.16+0.62 (+0.49%) ▲|PEP135.77-3.06 (-2.20%) ▼|PFE30.03-0.39 (-1.28%) ▼|PG161.02-3.48 (-2.12%) ▼|PLTR196.75+0.56 (+0.29%) ▲|PM199.47-2.27 (-1.13%) ▼|QCOM175.91+3.08 (+1.78%) ▲|RTX191.01-3.70 (-1.90%) ▼|SBUX100.80-1.11 (-1.09%) ▼|SCHW90.58-0.86 (-0.94%) ▼|SO92.89-0.93 (-0.99%) ▼|SPG211.63-0.41 (-0.19%) ▼|T20.93-1.81 (-7.96%) ▼|TMO673.82-2.72 (-0.40%) ▼|TMUS146.54-12.25 (-7.71%) ▼|TSLA372.22-2.36 (-0.63%) ▼|TXN284.69+5.19 (+1.86%) ▲|UBER66.70-2.37 (-3.43%) ▼|UNH418.09-6.89 (-1.62%) ▼|UNP292.87-5.22 (-1.75%) ▼|UPS101.06-0.46 (-0.45%) ▼|USB59.58-0.44 (-0.73%) ▼|V407.92-6.42 (-1.55%) ▼|VZ44.66-0.54 (-1.19%) ▼|WFC82.39-0.62 (-0.75%) ▼|WMT119.89-1.23 (-1.02%) ▼|XOM183.21+4.98 (+2.79%) ▲|
11.2 C
New York
Monday, October 26, 2026

Tag: cancer drugs

newsFORsourcecompanycontentinformation1releasesmarket

Florida Cancer Specialists & Research Institute Leadership Review of Step Therapy Policies Details Troubling Impacts to Cancer Patients

FORT MYERS, Fla., Oct. 20, 2026 /PRNewswire/ -- Insurer-driven step-editing practices in oncology continue to increase the risk of serious harm to cancer patients...

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs,...

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of...

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs,...

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of...

Florida Cancer Specialists & Research Institute Contributes to Two Significant FDA Approvals Advancing Breast and Pancreatic Cancer Care

FCS Clinical Research Continues to Pave the Way for Breakthrough TreatmentsFORT MYERS, Fla., Oct. 14, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute,...

Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options

FILKRI is available with a permanent Q-code, standardizing the billing and reimbursement process across all sites of care.RALEIGH, N.C., Oct. 12, 2026 /PRNewswire/ -- Accord...

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham 

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®

AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...

Florida Cancer Specialists & Research Institute Welcomes Medical Oncologist & Hematologist Nikhita Kathuria-Prakash, MD To Columbia County

FORT MYERS, Fla., Aug. 1, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that medical oncologist and hematologist Nikhita...

L.A. Times Owner Plans IPO—Because Newspapers Are the Future, Right?

Dr. Patrick Soon-Shiong is apparently planning to parade the financially beleaguered Los Angeles Times in front of the public eye, hoping that investors will...

June in Review: 14 Top Health Press Releases

A roundup of the most newsworthy healthcare press releases from PR Newswire, including a nasal spray for sleep apnea, a landmark study in clinical...

Florida Cancer Specialists & Research Institute Announces Addition Of Specialized Gynecologic Oncology Services in Tampa Bay Communities

Heather Miller, MD Joins Statewide Practice FORT MYERS, Fla., July 1, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) ) is pleased...

Cancer Therapeutics Market Forecast to Reach $168 Billion by 2029, Highlighting Recurrent and Metastatic Innovations

"Metastatic Cancer: A Significant Therapeutic Challenge as Pharmaceutical Companies Leverage Digital Platforms and Data to Enhance Engagement with Patients, Providers, and Regulators in the...

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

        

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCancer drugs

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers